16. First Gene Therapy For Parkinson’s Disease

Michael G. Kaplitt, Weill Cornell Medical College, Neurological Surgery, performed the world’s first gene therapy for Parkinson’s disease, marking the first-ever in vivo gene therapy in the brain for an adult neurological disease. The five-hour procedure, performed with the patient awake, was part of a FDA-approved phase I clinical trial, and the culmination of 15 years of research. The goal of Kaplitt’s gene therapy approach is to reset a specific group of cells that have become overactive in an affected part of the brain, causing the impaired movements of Parkinson’s disease. Kaplitt pinpoints the optimal location in the patient’s brain using information from an advanced 3T MRI image. This is merged with a CT scan, using the latest computer imaging technology. The final target is confirmed using fine electrical probes that identify the signature pattern of electrical activity of individual cells within the brain. The gene therapy agent (adeno-associated virus) is slowly delivered through a very fine catheter. After the infusion, the catheter is removed and the skin closed. This first of its kind clinical trial moves toward safe treatment of Parkinson’s disease and other brain disorders, using gene therapy.

› Back to Top  /  › Next Article  /  › Back to Listing

If you can see this message in a graphical web browser, then you are most likely using a non-modern browser. People who are using a graphical browser have the following options:

Upgrade to a modern generation web browser such as Mozilla, Opera, or for Mac users there is also Safari.

For people using early generation web browsers, such as Netscape 4, you can access the content of this page as is but there may be presentational errors.

Cornell University  
222 Day Hall
Ithaca, New York
14853-2801

P: 607.255.7200
F: 607.255.9030
E: VP Research
C: Credits

Cornell